.svg)
Results for the second quarter and first-half 2024
Total sales ended at MNOK 144.9, 5.5% above second quarter last year (MNOK137.4). This is a new record for a quarter. For the first half, sales ended at MNOK 278.7, 4.5% above last year (MNOK 266.6). Currency neutral sales of own products was up 1.7% for the quarter and 1.5% for the first half.
Recurring sales remain high at 73% (72%) for the quarter and 74% (71%) for the first half,underscoring the sustained momentum in utilization among our customers. Strong first half for the direct sales operations in EMEA delivers 17.3% currency neutral growth, while AMERICAS and APAC performances are influenced by strong comparable from last year, with a currency neutral growth of 1.4% for AMERICAS and a currency neutral decline of 23% for APAC.
Operating profit (EBIT) for the quarter ended at MNOK 41.3 giving a 28.5% EBIT margin (MNOK 42.2, a 30.7% margin). Similar for the first half was an operating profit of MNOK 73,3 (MNOK 75.7) giving a 26.3% EBIT margin (28.4%). Third-party sales increased 17.7% for the quarter and 12.8% for the first half. Medistim’s third-party distribution business signed a contract with the cardiovascular company Peters Surgical, to distribute their products in Sweden and Norway.
Solid cash position at quarter end with MNOK 107.1 and no long term interest-bearing debt. A dividend of NOK 4.50 (NOK 4.50) per share, a total of MNOK 82.4 was paid the 6th of May.
